Livdelzi: A New Hope for Primary Biliary Cholangitis Patients
At Starhope Liver Center, we are dedicated to pioneering treatment options for chronic liver
diseases. That’s why we’re proud to introduce our patients to Livdelzi, an exciting new therapy
approved by the U.S. FDA on August 14, 2024, for the treatment of Primary Biliary
Cholangitis (PBC). If you or a loved one is battling PBC, Livdelzi could be the breakthrough
you've been waiting for.
What is Livdelzi?
Livdelzi (seladelpar) is a first-in-class therapy developed specifically for adults with Primary
Biliary Cholangitis, a rare autoimmune liver disease. This chronic condition progressively
damages the bile ducts and can lead to cirrhosis or liver failure if left untreated. Livdelzi is
indicated:
● In combination with ursodeoxycholic acid (UDCA) for patients who have had an
inadequate response to UDCA.
● As monotherapy for those unable to tolerate UDCA.
This versatility makes Livdelzi a vital new option in the therapeutic arsenal against PBC.
How Livdelzi Works
At the core of Livdelzi’s innovation is its active compound, seladelpar, a highly selective
peroxisome proliferator-activated receptor delta (PPARδ) agonist. This mechanism
regulates key metabolic pathways and inflammatory processes in liver cells. It acts by:
● Activating fibroblast growth factor 21 (FGF21)
● Suppressing CYP7A1, the enzyme responsible for bile acid synthesis
● Resulting in reduced bile acid levels and inflammation, two critical issues in PBC
By directly addressing the underlying cellular dysfunction in PBC, Livdelzi not only manages
symptoms but targets the disease at its source.
Who Should Consider Livdelzi?
Livdelzi is recommended for adults diagnosed with PBC who:
● Show an inadequate biochemical response to UDCA despite long-term use
● Cannot tolerate UDCA due to side effects or contraindications
However, Livdelzi is not recommended for individuals with decompensated cirrhosis,
including those experiencing ascites, variceal bleeding, or hepatic encephalopathy. As always,
patient evaluation and monitoring by a hepatologist at Starhope Liver Center are essential.
Safety and Side Effects of Livdelzi
In clinical trials, Livdelzi was generally well tolerated, but some patients experienced:
●Headaches
●Abdominal pain or bloating
●Nausea
●Fractures (reported in 4% of patients)
●Liver enzyme elevations (particularly AST and ALT at higher doses)
●Dizziness
Regular liver function monitoring is advised to ensure optimal treatment safety and efficacy.
FDA Approval: What It Means
Livdelzi was granted accelerated approval by the FDA based on its ability to significantly
lower alkaline phosphatase (ALP) levels, a key biomarker of disease severity in PBC. While
long-term benefits on survival and liver failure prevention are still being studied, this approval
marks a crucial advancement in therapeutic options for PBC patients.
Why Starhope Liver Center Recommends Livdelzi
At Starhope Liver Center, we believe that Livdelzi represents not just a new drug—but a new
standard for personalized care in PBC. With its dual usage flexibility, targeted mechanism, and
robust biochemical response, Livdelzi is a welcome addition to our treatment protocols.
We are actively working with patients who may benefit from Livdelzi, providing guidance on
eligibility, insurance navigation, and close clinical monitoring.
Take the First Step with Livdelzi
If you're living with Primary Biliary Cholangitis, Livdelzi could be the treatment that brings you
closer to stability, comfort, and improved liver health. To learn more or schedule a consultation,
visit www.starhopeliver.com today. We're here to bring hope—one liver at a time.

